MMUT CRISPR/Cas9 gene therapy (CRISPR Therapeutics/National Institutes of Health/Rice University/Baylor College of Medicine)

N/A

Report date: 2025/01/26 16:25:55

Base Information

Drug NameMMUT CRISPR/Cas9 gene therapy (CRISPR Therapeutics/National Institutes of Health/Rice University/Baylor College of Medicine)
Drug Alias NameMethylmalonyl-coA mutase CRISPR/Cas9 gene therapy (CRISPR Therapeutics/National Institutes of Health/Rice University/Baylor College of Medicine)
ClassificationBiologics
Mechanisms of ActionMethylmalonyl-CoA Mutase modulators
TargetsMethylmalonyl-CoA Mutase
Therapy Area/IndicationsMethylmalonic acidaemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesRice UniversityNational Institutes Of HealthBaylor College Of Medicine +[4] 
Inactive CompaniesN/A
Active IndicationsMethylmalonic acidaemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A